Latanoprost/Timolol Eg (Latanoprost, Timolol)

Latanoprost increases the outflow of aqueous humor through the uveoscleral pathway by activating prostaglandin receptors. Timolol, a non‑selective beta‑blocker, decreases aqueous humor production by blocking β‑adrenergic receptors in the ciliary body. Together they achieve a greater pressure‑lowering effect.

The dosing regimen is determined by the prescribing clinician based on the patient’s intraocular pressure, response, and tolerance. Typically, one drop is instilled in the affected eye(s) once daily, but the exact schedule must follow the healthcare professional’s instructions.

Safety data are limited, and the pregnancy category is unknown. The medication should only be used during pregnancy or lactation if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified physician.

Enquiries are submitted via the product page at gnhindia.com where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy agents, the latanoprost/timolol combination offers dual mechanisms—enhanced outflow and reduced production—resulting in greater intraocular pressure reduction. This can be advantageous for patients who need stronger control or who have not achieved target pressure with a single agent.

Store the eye‑drop bottles at ambient temperature, preferably below 25 °C. Keep them in the original packaging, protect from direct light and moisture, and discard any product that appears discolored or has particles.

The medication is applied topically to the eye. The patient should wash their hands, tilt the head back, pull down the lower eyelid, and place a single drop into the conjunctival sac. Close the eye gently for a few seconds and avoid blinking excessively.

Serious adverse events include severe ocular inflammation, sudden loss of vision, systemic bradycardia, hypotension, and bronchospasm in susceptible individuals. Any sudden eye pain, vision changes, or systemic symptoms should prompt immediate medical evaluation.

Patients with known hypersensitivity to latanoprost, timolol, or any excipients should avoid the product. It is also contraindicated in individuals with severe asthma, chronic obstructive pulmonary disease, certain heart block conditions, or active ocular infections without prior medical clearance.